The therapy sustained IDFS benefit compared with ET alone.
American Institute of the History of Pharmacy posts the collection of pharmacist Daniel Shifrin on its website.
This expansion of their role goes beyond traditional dispensing duties, positioning pharmacists as an essential bridge between patients and the broader health care system.
Offering pharmacy professionals insights into the benefits, importance and challenges associated with switching patients to long-acting injectables to treat schizophrenia.
Douglas Adkins, MD shares key data and findings from the phase 3 KEYNOTE-689 study.
Tuberculosis is a long-standing global health issue that requires continued public health vigilance to prevent a resurgence of this preventable and curable disease.
In this retrospective study, investigators evaluated a pharmacy-led initiative in the emergency department (ED), finding a potential reduction in ED revisits and hospital readmissions, though results were not statistically significant.
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
With the release of the 2022 AHA/ACC Guidelines for the Management of Heart Failure, patients with HFpEF now have a wider range of treatment options.
The Pharmacy Quality Alliance developed the “Medication Access Framework for Quality Measurement” to address the social determinants of health that hinder patient medication access and contribute to poor health outcomes.
Panelists share final thoughts and advice regarding the critical role pharmacy has played and continues to play in public health initiatives.
Glucagon-like peptide-1 (GLP-1) analogs demonstrate potential to address multiple pathological processes in Alzheimer disease, with promising early research suggesting cognitive improvements and potential for future treatment.
Metformin has been the drug of choice for the treatment of diabetes since the 1950s, but new changes suggest the consideration of SGLT-2 inhibitors or GLT-1 agonists.
The adjuvant therapy has demonstrated varied efficacy for patients.
The cost of defending license matters and malpractice claim costs have increased over a 5-year period (2017-2022).
Raising awareness of the potentially fatal cardiovascular complications of epinephrine toxicity.
Diversity, equity, and inclusion programs in pharmacy can lead to better health outcomes for patients.
In recent years, telestroke services have transformed stroke care delivery, especially in rural or underserved areas.
By examining the evidence, pharmacists can gain insights into whether these supplements could be integrated into MS treatment regimens to improve patient outcomes.
Implementing these standards can be logistically challenging.
Experts share operational challenges and patient care implications of the Inflation Reduction Act's (IRA) drug pricing reforms.
Artificial intelligence holds immense potential to address the rising demand for oncology services and improve patient outcomes by facilitating more effective, efficient, personalized cancer care.
They can continue to put pressure on companies and regulatory bodies to make the system work for them and not the other way around.
Pharmacists must understand the value of monitoring changes in quality of life and headache frequency to help facilitate the decision to continue, discontinue, or restart migraine prophylaxis.
An increase in the use of GLP-1 agonists for weight loss is affecting patients with diabetes who rely on these medications.
With many people remaining to be vaccinated against COVID-19 and everyone 6 months and older needing an annual influenza vaccine for the 2021-2022 season, many pharmacies are turning to pharmacy technicians to assist in the process.